Estimated 2026 sales: $22.3 billion
2019 sales: $21.7 billion
2019-26 CAGR: 0.4%
Gilead Sciences has been in the spotlight for the past few months for remdesivir, the drugmaker's repurposed antiviral with an emergency use authorization from the FDA in COVID-19 patients. However, it's HIV medicines that have been the company's bread and butter as of late, and they may not be enough to churn out big sales for Gilead in the coming years.
The Big Biotech may be looking at measly growth ahead, with Evaluate forecasting just a 0.4% increase in annual sales each year through 2026. That rate would put Gilead at $22.3 billion in sales in 2026—a pretty slim bump from its 2019 total of $21.7 billion.
That meager forecast would likely factor in a slowdown from Gilead's HIV portfolio, headlined by blockbuster Biktarvy and its $4.74 billion in 2019 sales. But that's not to say Gilead doesn't have blockbuster potential in its non-HIV pipeline. According to Evaluate, JAK inhibitor filgotinib, which is already facing an FDA review in rheumatoid arthritis, could pull in around $1.28 billion in annual sales by 2024.
Gilead commercial chief Johanna Mercier, speaking in January at the J.P. Morgan Healthcare Conference, focused on the strength of filgotinib's clinical data and said physician feedback has so far been very positive. The company foresees a total of five indications for filgotinib launching in the next four years, so it’s keeping not only the short term but also the medium-to-long term in mind, she said.
Filgotinib has already been filed for approval in Europe and Japan, but the U.S. market is where the big bucks will come from. Recent data readouts showed the medication is better than methotrexate alone and suggested it has an edge over AbbVie’s Humira, the aging blockbuster rheumatoid arthritis incumbent.